TW221418B - - Google Patents

Info

Publication number
TW221418B
TW221418B TW080101154A TW80101154A TW221418B TW 221418 B TW221418 B TW 221418B TW 080101154 A TW080101154 A TW 080101154A TW 80101154 A TW80101154 A TW 80101154A TW 221418 B TW221418 B TW 221418B
Authority
TW
Taiwan
Application number
TW080101154A
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Application granted granted Critical
Publication of TW221418B publication Critical patent/TW221418B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW080101154A 1990-02-08 1991-02-12 TW221418B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/477,024 US5227375A (en) 1990-02-08 1990-02-08 Aromatase inhibitors

Publications (1)

Publication Number Publication Date
TW221418B true TW221418B (zh) 1994-03-01

Family

ID=23894189

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080101154A TW221418B (zh) 1990-02-08 1991-02-12

Country Status (10)

Country Link
US (1) US5227375A (zh)
AU (1) AU7150991A (zh)
GR (1) GR910100067A (zh)
IE (1) IE65269B1 (zh)
IL (1) IL97122A (zh)
MY (1) MY105479A (zh)
NZ (1) NZ236966A (zh)
TW (1) TW221418B (zh)
WO (1) WO1991012206A2 (zh)
ZA (1) ZA91604B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519051A (en) * 1991-03-28 1996-05-21 Teikoku Hormone Mfg. Co., Ltd. Oxa- or azasteroid derivatives
AU665455B2 (en) * 1992-09-30 1996-01-04 Teikoku Hormone Mfg. Co., Ltd. Novel 7-substituted oxa- or azasteroid compound
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
EP1094798A2 (en) * 1998-03-11 2001-05-02 Endorecherche Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2001014406A1 (fr) * 1999-08-23 2001-03-01 Chugai Seiyaku Kabushiki Kaisha Agents anti-androgènes
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
IL164159A0 (en) * 2002-03-22 2005-12-18 Pharmacia Corp C-17 spirolactonization and 6,7 oxidation of steroids
AU2003220139A1 (en) * 2002-11-07 2004-06-03 Pharmacia & Upjohn Company Llc Processes for preparing c-7 substituted 5-androstenes
US8183401B2 (en) * 2004-01-16 2012-05-22 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
CA2837494C (en) * 2010-05-20 2019-12-31 University Of Saskatchewan Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
BR112015026298A8 (pt) 2013-04-19 2019-12-24 Univ Saskatchewan veículo de dispensação para a dispensação de um inibidor da aromatase

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125071C (zh) * 1963-12-24
US3380886A (en) * 1965-04-07 1968-04-30 Upjohn Co 7alpha-methyl-3beta-hydroxy-5-androstenes
US3591607A (en) * 1966-04-19 1971-07-06 Hoffmann La Roche Retrosteroid a-ring formation
US3766213A (en) * 1966-04-19 1973-10-16 Hoffmann La Roche Retrosteroid a ring formation
US3485828A (en) * 1967-04-10 1969-12-23 Syntex Corp 6,7-ethylene and 6,7-substituted ethylene derivatives of the pregnane series
US3952018A (en) * 1972-01-14 1976-04-20 Hoffmann-La Roche Inc. 15-Oxasteroids
DE2558088C2 (de) * 1975-12-19 1985-05-30 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 4-Androsten-3,17-dion-Derivaten
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4451404A (en) * 1983-02-09 1984-05-29 The Upjohn Company 16β-Methyl steroid process
US4596796A (en) * 1983-09-12 1986-06-24 Sumitomo Chemical Company, Limited Dithiolphosphoric acid ester as a soil pesticide
DE3612632A1 (de) * 1986-04-11 1987-10-22 Schering Ag Verfahren zur herstellung von 7(alpha)-propylsteroiden
GB8617107D0 (en) * 1986-07-14 1986-08-20 Erba Farmitalia 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
GB8622330D0 (en) * 1986-09-17 1986-10-22 Erba Farmitalia 4-substituted 6-alkylidenandrostene-3,17-dione derivatives

Also Published As

Publication number Publication date
IL97122A0 (en) 1992-05-25
IE910263A1 (en) 1991-08-14
GR910100067A (el) 1992-06-30
IL97122A (en) 1996-06-18
AU7150991A (en) 1991-09-03
MY105479A (en) 1994-10-31
WO1991012206A2 (en) 1991-08-22
NZ236966A (en) 1993-11-25
US5227375A (en) 1993-07-13
WO1991012206A3 (en) 1991-11-28
ZA91604B (en) 1992-09-30
IE65269B1 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
DE4191314T1 (zh)
DK17290D0 (zh)
DE4190714T (zh)
FR2658754B1 (zh)
DE4192810T (zh)
DE4193006T (zh)
FR2666916B1 (zh)
FR2669529B1 (zh)
FR2665854B1 (zh)
FR2659840B1 (zh)
DE4191484T (zh)
FR2657929B1 (zh)
FR2668272B1 (zh)
FR2658201B1 (zh)
FR2656909B1 (zh)
JPH0490149U (zh)
DE4190938T (zh)
FR2669677B1 (zh)
FR2669898B1 (zh)
IN173014B (zh)
ECSM90473U (zh)
IN176005B (zh)
IN175895B (zh)
IN175893B (zh)
IN175891B (zh)